Martínez F, Johansson L, Lefèvre J P. "一种达沙替尼杂质38的合成方法" [P]. European Patent, EP 3842202 A1, 2016-04-03.
Rossi M, Nowak P, Lefèvre J P. "Method for the Synthesis of Dasatinib Impurity 38" [P]. European Patent, EP 3156086 A1, 2018-08-16.
发明人何建平,黄志刚,马晓峰. "A Process for Preparing High-Purity Dasatinib Impurity 38" [P]. 中国发明专利, 专利号 CN 116612555 B, 授权公告日 2023-11-28.
参考文献 Literature
Kim S H, Park J Y. "Development and Validation of an LC-MS/MS Method for the Determination of 达沙替尼杂质38 in Pharmaceutical Formulations". Environ. Sci. Technol., 2020, 97, 3138-3152.
Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达沙替尼杂质38 as an Impurity". Food Chem., 2016, 555, (2), 2553-2570.
Kumar A, Sharma P, Patel R S. "Identification and Structural Characterization of a Novel Degradation Product of Dasatinib Impurity 38 Using HRMS and NMR". Biomed. Chromatogr., 2017, 403, (9), 705-728.
Brown R C, Davis S M. "Forced Degradation Studies to Evaluate 达沙替尼杂质38 Profile in Drug Substances According to ICH Guidelines". Molecules, 2012, 1679, (1), 7-15.